{"id":7155,"date":"2026-08-11T14:31:00","date_gmt":"2026-08-11T14:31:00","guid":{"rendered":"https:\/\/cielcharlotte.com\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\/"},"modified":"2026-08-11T14:31:00","modified_gmt":"2026-08-11T14:31:00","slug":"vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight","status":"publish","type":"post","link":"https:\/\/development.brstdev.com\/cielcharlotte\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\/","title":{"rendered":"Vascular Dementia Market is Projected to Boost at a Moderate Growth Rate of 4.5% During the Forecast Period (2026-2036) | DelveInsight"},"content":{"rendered":"<div class=\"prn-meta\"><span class=\"prn-company\">DelveInsight Business Research, LLP<\/span><span>August 11, 2026<\/span><\/div>\n<div class=\"prn-body\">\n<p><b><i>The vascular dementia market is expected to increase due to the rising prevalence of the disease driven by the aging global population, the growing incidence of stroke and other vascular risk factors, and improved diagnostic capabilities enabling earlier and more accurate detection. Additionally, the launch of emerging therapies such as Apabetalone (Resverlogix), BAC (Charsire Biotechnology), PNA1 (ProNeurogen), Rifaximin SSD (Bausch Health), PNA5 (ProNeurogen), and others will further propel the market growth.<\/i><\/b><\/p>\n<p><span class=\"legendSpanClass\">LAS VEGAS<\/span>, <span class=\"legendSpanClass\">Aug. 11, 2026<\/span> \/PRNewswire\/ &#8212; Recently published Vascular Dementia Market Insights report includes a comprehensive understanding of current treatment practices, vascular dementia emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n                    <img decoding=\"async\" src=\"https:\/\/mmx.prnewswire.com\/media\/MS1196378\/logo-png.jpg?id=OA2855019\" title=\"DelveInsight Logo\" alt=\"DelveInsight Logo\"><\/img>\n                <\/p>\n<\/p><\/div>\n<p><b>Vascular Dementia Market Summary<\/b><\/p>\n<ul type=\"disc\">\n<li>The market size for vascular dementia\u00a0was found to be <b>USD 1.3 billion<\/b>\u00a0in the 7MM in 2025.<\/li>\n<li>The United States accounted for the largest vascular dementia\u00a0treatment market size, approximately <b>70%<\/b>\u00a0of the total market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.<\/li>\n<li>The 7MM accounted for approximately <b>3 million<\/b>\u00a0diagnosed prevalent cases of vascular dementia in 2025, highlighting the substantial and growing burden of vascular cognitive impairment across major global healthcare markets.<\/li>\n<li>Leading vascular dementia companies, such as <b>Resverlogix, Charsire Biotechnology, ProNeurogen, Bausch Health, Hemostemix, SciNeuro Pharmaceuticals, Can-Fite Biopharma, Primary Peptides, Autifony Therapeutics, Zhittya Genesis Medicine,<\/b>\u00a0and others, are developing new vascular dementia treatment\u00a0drugs that can be available in the vascular dementia market in the coming years.\u00a0<\/li>\n<li>The promising vascular dementia therapies in clinical trials include <b>Apabetalone, BAC, PNA1, Rifaximin SSD, PNA5, ACP-01, SNP318, Piclidenoson, K13V, Research program: neurovascular channel, Research program: Fibroblast growth factor 1, <\/b>and others.<\/li>\n<\/ul>\n<p>Discover new treatment for vascular dementia @ <a href=\"https:\/\/www.delveinsight.com\/report-store\/vascular-dementia-market?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"nofollow\"><b>https:\/\/www.delveinsight.com\/report-store\/vascular-dementia-market<\/b><\/a><\/p>\n<p><b>Key Factors Driving the Growth of the Vascular Dementia Market<\/b>\u00a0<\/p>\n<ul type=\"disc\">\n<li><b>Rising Prevalence of Vascular Dementia: <\/b>The increasing global burden of aging populations and cerebrovascular diseases is driving the incidence of vascular dementia. Improved life expectancy has led to a larger at-risk population, expanding the demand for effective diagnostic and therapeutic solutions.<\/li>\n<li><b>Growing Burden of Cardiovascular Risk Factors: <\/b>Higher rates of hypertension, diabetes, obesity, atrial fibrillation, and stroke are contributing significantly to vascular dementia cases. The increasing prevalence of these underlying conditions is expected to fuel long-term market growth.<\/li>\n<li><b>Advancements in Diagnostic Technologies:<\/b>\u00a0Innovations in neuroimaging, blood-based biomarkers, and AI-assisted diagnostic tools are enabling earlier and more accurate diagnosis of vascular dementia. Early detection supports timely intervention and increases the adoption of diagnostic services.<\/li>\n<li><b>Increasing Research and Drug Development Activities: <\/b>Pharmaceutical companies such as <b>Resverlogix <\/b>(Apabetalone), <b>Charsire Biotechnology<\/b>\u00a0(BAC), <b>ProNeurogen <\/b>(PNA1 and PNA5), <b>Bausch Health<\/b>\u00a0(Rifaximin SSD), <b>Hemostemix <\/b>(ACP-01),<b>\u00a0SciNeuro Pharmaceuticals<\/b>\u00a0(SNP318), and others are investing in novel therapeutics targeting neurovascular dysfunction, inflammation, and cognitive decline. A growing clinical pipeline is creating optimism for disease-modifying treatment options.<\/li>\n<\/ul>\n<p>Download the report to understand the top emerging vascular dementia drugs\u00a0@\u00a0<a href=\"https:\/\/www.delveinsight.com\/sample-request\/vascular-dementia-market?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"nofollow\"><b>Vascular Dementia Clinical Trials<\/b><\/a><\/p>\n<p><i>As per Aparna Thakur, Project Manager of Forecasting at DelveInsight, Apabetalone is expected to achieve a medium uptake following its anticipated launch in 2032. Peak market share is projected to vary across markets, reaching approximately 14% at its highest level, with uptake stabilizing over 7 years to peak adoption. The moderate uptake outlook reflects the potential clinical value of the therapy while accounting for competition from existing standards of care and other emerging therapies entering the vascular dementia landscape.<\/i><\/p>\n<p><i>DelveInsight&#8217;s Vascular Dementia Market Report delivers executive-level intelligence on the evolving market landscape, integrating epidemiology, treatment practices, competitive dynamics, emerging therapies, and market forecasts across the major markets through 2036. Built on a rigorous methodology combining comprehensive secondary research, primary interviews with key opinion leaders and industry experts, and proprietary patient-based forecasting models, the report provides a reliable foundation for strategic planning. Designed for pharmaceutical and biotech executives, it enables informed decisions on portfolio strategy, business development, market entry, investment prioritization, and commercial planning.<\/i>\u00a0<\/p>\n<p><b>Vascular Dementia Market Analysis<\/b><\/p>\n<ul type=\"disc\">\n<li>The primary objectives of vascular dementia treatment are to enhance cognitive function, preserve daily functioning, improve behavioral symptoms, slow disease progression, and address neuropsychiatric complications such as depression and anxiety.\u00a0<\/li>\n<li>Although research has significantly advanced the understanding of vascular dementia, there are currently no approved pharmacological therapies specifically indicated for its treatment. This unmet medical need continues to place a considerable burden on patients, caregivers, and healthcare systems.<\/li>\n<li>Current management strategies primarily focus on controlling underlying vascular risk factors and alleviating symptoms. Patients are commonly treated with medications such as <b>antihypertensives, anticoagulants, vasodilators, antidiabetic agents, antipsychotics, and other supportive therapies<\/b>\u00a0to help reduce the risk of further vascular damage and disease progression.\u00a0<\/li>\n<li><b>Cholinesterase inhibitors<\/b>\u00a0may be prescribed to improve cognitive symptoms, while antidepressants are often used to manage depression and other behavioral or psychiatric manifestations.\u00a0<\/li>\n<li><b>Vasodilators<\/b>\u00a0enhance cerebral blood flow by reducing blood vessel constriction, and antiplatelet agents such as aspirin help lower the risk of recurrent vascular events through inhibition of cyclooxygenase (COX)-mediated prostaglandin synthesis.\u00a0<\/li>\n<li>In addition, NMDA receptor antagonists, including memantine and nicardipine, have shown modest potential in slowing cognitive decline in some patients.<\/li>\n<li>Although medications approved for Alzheimer&#8217;s disease, including <b>donepezil, galantamine, rivastigmine, and memantine<\/b>, are not specifically indicated for vascular dementia, they may be prescribed for individuals with mixed dementia, where vascular pathology coexists with Alzheimer&#8217;s disease.<\/li>\n<li>The vascular dementia pipeline remains relatively limited but is evolving toward more mechanism-driven approaches. Investigational therapies such as <b>Apabetalone <\/b>by Resverlogix, <b>BAC <\/b>by Charsire Biotechnology, <b>Rifaximin SSD<\/b>\u00a0by Bausch Health, and <b>PNA1 <\/b>by ProNeurogen highlight an increasing emphasis on vascular modulation, epigenetic regulation, and cardiometabolic pathways.\u00a0<\/li>\n<li>These targeted strategies aim to preserve cerebrovascular integrity and cognitive function, potentially driving future advances in vascular dementia treatment.<\/li>\n<\/ul>\n<p><b>Vascular Dementia Competitive Landscape<\/b><\/p>\n<p>Some of the vascular dementia drugs under development include <b>Apabetalone <\/b>(Resverlogix), <b>BAC<\/b>\u00a0(Charsire Biotechnology), <b>PNA1 <\/b>(ProNeurogen), <b>Rifaximin SSD<\/b>\u00a0(Bausch Health), <b>PNA5 <\/b>(ProNeurogen), <b>ACP-01<\/b>\u00a0(Hemostemix), <b>SNP318 <\/b>(SciNeuro Pharmaceuticals), and others.<\/p>\n<p><b>Resverlogix&#8217;s Apabetalone<\/b>\u00a0is the first therapy in a novel class of drugs developed to regulate proteins associated with disease progression. Unlike conventional treatments that typically target a single disease-causing pathway, apabetalone inhibits bromodomain and extraterminal (BET) proteins, enabling it to influence multiple biological mechanisms involved in chronic and complex diseases. This multi-targeted approach represents a potential shift in the treatment paradigm for chronic disorders.<\/p>\n<p>Apabetalone exerts its effects at the transcriptional level through a distinctive mechanism of action. As a selective BET protein inhibitor, it helps restore normal gene expression by modulating abnormal epigenetic processes that contribute to the development and progression of numerous chronic diseases.<\/p>\n<p><b>Charsire Biotechnology&#8217;s BAC<\/b>\u00a0is an investigational anti-inflammatory therapy composed of a Multi-Glycan Complex (MGC) derived from soybean extract. It is being developed to alleviate neuroinflammation associated with vascular dementia. In the clinical study, eligible participants were randomized in a 3:1 ratio and stratified by dementia subtype (Alzheimer&#8217;s disease or non-Alzheimer&#8217;s disease) to receive either topical BAC or a matched vehicle control. The treatment was applied to the external nasal skin, scalp, and neck twice daily at a total dose of 30 g per day.<\/p>\n<p><b>ProNeurogen&#8217;s PNA-1 <\/b>is an investigational therapy being evaluated for vascular cognitive impairment and dementia (VCID), chronic bone cancer pain, and traumatic brain injury. It is a native angiotensin-(1-7) [Ang-(1-7)] peptide that exerts its therapeutic effects by selectively targeting the MAS receptor.<\/p>\n<p><b>Bausch Health&#8217;s Rifaximin Soluble Solid Dispersion (SSD)<\/b>\u00a0is being investigated as a potential treatment for vascular dementia. In a single-blind, placebo-controlled Phase Ib\/IIa trial, the therapy demonstrated a favorable safety and tolerability profile while showing improvements in systemic inflammation and dementia-related biomarkers, likely through modulation of gut microbiota function. The current study aims to assess the effects of rifaximin SSD compared with placebo on gut microbial composition and activity, cognitive performance, functional outcomes, and caregiver burden in patients with vascular dementia.<\/p>\n<p>The anticipated launch of these emerging therapies are poised to transform the vascular dementia\u00a0market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the vascular dementia\u00a0market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.<\/p>\n<p>Discover more about which pipeline drugs could transform vascular dementia treatment @ <a href=\"https:\/\/www.delveinsight.com\/sample-request\/vascular-dementia-market?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"nofollow\"><b>Vascular Dementia Medications<\/b><\/a><\/p>\n<p><b>Vascular Dementia Epidemiology Segmentation<\/b><\/p>\n<p>The vascular dementia\u00a0epidemiology section provides insights into the historical and current vascular dementia\u00a0patient pool and forecasted trends for the leading markets. In 2025, the US accounted for the largest share of diagnosed prevalent cases of vascular dementia across the 7MM, with an estimated <b>1 million<\/b>\u00a0cases, underscoring its dominant epidemiological burden in this cohort.<\/p>\n<p>The vascular dementia\u00a0treatment market report\u00a0proffers epidemiological analysis for the study period 2022\u20132036 in the leading markets, segmented into:<\/p>\n<ul type=\"disc\">\n<li>Total Prevalent Cases of Dementia<\/li>\n<li>Total Diagnosed Prevalent Cases of Dementia\u00a0<\/li>\n<li>Total Diagnosed Prevalent Cases of Vascular Dementia\u00a0<\/li>\n<li>Age-specific Diagnosed Prevalent Cases of Vascular Dementia\u00a0<\/li>\n<li>Etiology-specific Diagnosed Prevalent Cases of Vascular Dementia<\/li>\n<li>Total Treated Cases of Vascular Dementia<\/li>\n<\/ul>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Vascular Dementia Market Report Metrics<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Details<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Study Period<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">2022\u20132036<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Coverage<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Vascular Dementia Market CAGR<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">4.5\u00a0%<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Vascular Dementia Market Size in 2025<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">USD 1.3 Billion<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Key Vascular Dementia Companies<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Resverlogix, Charsire Biotechnology, ProNeurogen, Bausch Health, Hemostemix, SciNeuro Pharmaceuticals, Can-Fite Biopharma, Primary Peptides, Autifony Therapeutics, Zhittya Genesis Medicine, and others<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Key\u00a0Vascular Dementia\u00a0Therapies<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Apabetalone, BAC, PNA1, Rifaximin SSD, PNA5, ACP-01, SNP318, Piclidenoson, K13V, Research program: neurovascular channel, Research program: Fibroblast growth factor 1, and others<\/span><\/p>\n<\/td>\n<\/tr>\n<\/table>\n<\/div>\n<p><b>Scope of the <\/b><b>Vascular Dementia<\/b><b>\u00a0Market Report<\/b><\/p>\n<ul type=\"disc\">\n<li>Vascular Dementia Patient Population Forecast<\/li>\n<li>Vascular Dementia Therapeutics Market Size<\/li>\n<li>Vascular Dementia Pipeline Analysis<\/li>\n<li>Vascular Dementia Market Size and Trends<\/li>\n<li>Vascular Dementia Market Opportunity<\/li>\n<li>Vascular Dementia Market Unmet Needs<\/li>\n<li>KOL&#8217;s Views on Vascular Dementia<\/li>\n<li>Vascular Dementia Market Access and Reimbursement<\/li>\n<\/ul>\n<p><b>Table of Contents<\/b><\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">1<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Vascular Dementia Market Key Insights<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">2<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Vascular Dementia Market Report Introduction<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">3<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Vascular dementia Market Overview at a Glance<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">3.1<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Market Share (%) Distribution of Vascular Dementia by Therapies in the 7MM in 2025<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">3.2<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Market Share (%) Distribution of Vascular Dementia by Therapies in the 7MM in 2036<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">4<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Executive Summary<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">5<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Key Events<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">6<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Disease Background and Overview: Vascular dementia<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">6.1<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Introduction<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">6.2<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Types of Vascular Dementia<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">6.3<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Signs and Symptoms<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">6.4<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Causes<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">6.5<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Risk Factors<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">6.6<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Pathophysiology and Molecular Mechanism of Vascular Dementia<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">6.7<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Biomarkers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">6.8<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Diagnosis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">6.9<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Treatment and Management<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">6.10<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Diagnosis and Treatment Guidelines<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">7<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Epidemiology and Market Methodology<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">8<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Epidemiology and Patient Population<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">8.1<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Key Findings on Patient Burden in Vascular dementia<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">8.2<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Assumptions and Rationale: 7MM<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">8.2.1<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Total Prevalent Cases of Dementia\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">8.2.2<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Total Diagnosed Prevalent Cases of Dementia\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">8.2.3<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Total Diagnosed Prevalent Cases of Vascular Dementia\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">8.2.4<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Age-specific Diagnosed Prevalent Cases of Vascular Dementia\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">8.2.5<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Etiology-specific Diagnosed Prevalent Cases of Vascular Dementia\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">8.2.6<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Treated Cases of Vascular dementia<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">8.3<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Total Diagnosed Prevalent Cases of vascular dementia in the 7MM<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">8.4<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">The United States<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">8.4.1<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Total Prevalent Cases of Dementia in the US\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">8.4.2<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Total Diagnosed Prevalent Cases of Dementia in the US<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">8.4.3<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Total Diagnosed Prevalent Cases of Vascular Dementia in the US<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">8.4.4<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Age-specific Diagnosed Prevalent Cases of Vascular Dementia in the US<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">8.4.5<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Etiology-specific Diagnosed Prevalent Cases of Vascular Dementia in the US<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">8.4.6<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Treated Cases of vascular dementia in the US<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">8.5<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">EU4 and the UK<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">8.6<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Japan<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">9<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Patient Journey<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">10<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Emerging Therapies: Vascular dementia<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">10.1<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Competitive Landscape: Emerging Vascular Dementia Drugs<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">10.2<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Apabetalone: Resverlogix<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">10.2.1<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Drug Description<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">10.2.2<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Other Developmental Activities<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">10.2.3<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Clinical Trials Information<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">10.2.4<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Safety and Efficacy<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">10.2.5<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Analysts&#8217; Views<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">10.3<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">BAC: Charsire Biotechnology<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">10.4<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">PNA1: ProNeurogen<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">10.5<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Rifaximin SSD: Bausch Health<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"2\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><i>To be continued in the report\u2026<\/i><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">11<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Vascular Dementia Market : 7MM Market Analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">11.1<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Vascular Dementia Market Key Findings and Insights<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">11.2<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Key Market Forecast Assumptions<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">11.3<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Vascular Dementia Market Outlook<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">11.4<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Attribute Analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">11.5<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Total Market Size of Vascular Dementia in the 7MM<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">11.6<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Market Size of Vascular Dementia by Therapies in the 7MM<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">11.7<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Market Size of Vascular Dementia in the United States<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">11.7.1<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Total Market Size of Vascular Dementia in the United States<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">11.7.2<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Market Size of Vascular Dementia by Therapies in the United States<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">11.8<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Market Size of Vascular Dementia in EU4 and the UK<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">11.9<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Market Size of Vascular Dementia in Japan<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">12<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Key Opinion Leaders&#8217; Views<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">13<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Unmet Needs<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">14<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">SWOT Analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">15<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Market Access and Reimbursement<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">15.1<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">The United States<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">15.2<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">In EU4 and the UK<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">15.3<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Japan<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">16<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Appendix<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">17<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Acronyms and Abbreviations<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">18<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Bibliography<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">19<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Vascular Dementia Market Report Methodology<\/span><\/p>\n<\/td>\n<\/tr>\n<\/table>\n<\/div>\n<p><b>Related Reports<\/b><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/vascular-dementia-pipeline-insight?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"nofollow\"><b>Vascular Dementia Clinical Trial Analysis<\/b><\/a><\/p>\n<p><b>Vascular Dementia<\/b><b>\u00a0Pipeline Insight <\/b><b>\u2013<\/b><b>\u00a02026<\/b>\u00a0report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key vascular dementia companies, including<b>\u00a0Merz Pharma, CSPC Ouyi Pharmaceutical, Resverlogix Corporation, Autifony Therapeutics, Beijing Joekai Biotechnology, Neuraltus Pharmaceuticals, <\/b>and others.<\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/dementia-market?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"nofollow\"><b>Dementia Market<\/b><\/a><\/p>\n<p><b>Dementia Market Insights, Epidemiology, and Market Forecast \u2013 2036 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key dementia companies, including <b>Eli Lilly and Company, Biogen, Eisai Co., Ltd., Roche, Novo Nordisk, Alzheon, Cortexyme (Quince Therapeutics), Cassava Sciences, AC Immune, TauRx Therapeutics, Annovis Bio, Prothena, Neurim Pharmaceuticals, Cognition Therapeutics, Denali Therapeutics, Alnylam Pharmaceuticals, Johnson &amp; Johnson, Pfizer, AbbVie, Otsuka Pharmaceutical,<\/b>\u00a0and others.<\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"nofollow\"><b>Alzheimer&#8217;s Disease <\/b><b>Market<\/b><\/a><\/p>\n<p><b>Alzheimer&#8217;s Disease<\/b><b>\u00a0Market Insights, Epidemiology, and Market Forecast <\/b><b>\u2013 <\/b><b>2036 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer&#8217;s disease companies, including <b>Novo Nordisk, Eli Lilly, Suven Life Sciences, Bristol Myers Squibb, IGC Pharma, T3D Therapeutics, Lexeo Therapeutics, Axsome Therapeutics, Araclon Biotech S.L., Eisai, TauRx Therapeutics, GemVax &amp; KAEL, AC Immune SA, Johnson &amp; Johnson, Longeveron, Vaccinex, Sinaptica Therapeutics<\/b><b>, <\/b>and others.<\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/dementia-related-psychosis-market?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"nofollow\"><b>Dementia-related Psychosis Market<\/b><\/a><\/p>\n<p><b>Dementia-related Psychosis Market Insights, Epidemiology, and Market Forecast \u2013 2036 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key dementia-related psychosis companies, including <b>Acadia Pharmaceuticals, Bristol Myers Squibb, Cognition Therapeutics, Maplight Therapeutics, Johnson &amp; Johnson, AgeneBio,<\/b>\u00a0and others.<\/p>\n<p><b>About<\/b>\u00a0<b>DelveInsight<\/b><\/p>\n<p>DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.\u00a0Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform\u00a0PharmDelve<b>.<\/b><\/p>\n<p><b>Contact Us<br \/><\/br><\/b>Shruti Thakur <br \/><\/br><a href=\"mailto:info@delveinsight.com\" target=\"_blank\" rel=\"nofollow\">info@delveinsight.com<\/a> <br \/><\/br>+14699457679<br \/><\/br><a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com<\/a><\/p>\n<p>\u00a0<\/p>\n<p id=\"PURL\"><img decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=IO23660&amp;sd=2026-08-11\"><\/img> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-20262036--delveinsight-302847923.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-20262036&#8211;delveinsight-302847923.html<\/a><\/p>\n<p>SOURCE DelveInsight Business Research, LLP<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO23660&amp;Transmission_Id=202608111031PR_NEWS_USPR_____IO23660&amp;DateId=20260811\" style=\"border:0px;width:1px;height:1px\"><\/img><\/div>\n<p class=\"prn-disclaimer\">Distributed by PR Newswire \/ Cision.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The vascular dementia market is expected to increase due to the rising prevalence of the disease driven by the aging global population, the growing incidence of stroke and other vascular risk factors, and improved diagnostic capabilities enabling earlier\u2026<\/p>\n","protected":false},"author":15,"featured_media":7156,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[23],"tags":[19],"class_list":["post-7155","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-artwork","tag-pr-post"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vascular Dementia Market is Projected to Boost at a Moderate Growth Rate of 4.5% During the Forecast Period (2026-2036) | DelveInsight - Ciel Charlotte<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vascular Dementia Market is Projected to Boost at a Moderate Growth Rate of 4.5% During the Forecast Period (2026-2036) | DelveInsight - Ciel Charlotte\" \/>\n<meta property=\"og:description\" content=\"The vascular dementia market is expected to increase due to the rising prevalence of the disease driven by the aging global population, the growing incidence of stroke and other vascular risk factors, and improved diagnostic capabilities enabling earlier\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/development.brstdev.com\/cielcharlotte\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\/\" \/>\n<meta property=\"og:site_name\" content=\"Ciel Charlotte\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-11T14:31:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/08\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight-ai.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Maya Collins\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Maya Collins\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\\\/\"},\"author\":{\"name\":\"Maya Collins\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/2d677d9028fd00936e6868e285e439fb\"},\"headline\":\"Vascular Dementia Market is Projected to Boost at a Moderate Growth Rate of 4.5% During the Forecast Period (2026-2036) | DelveInsight\",\"datePublished\":\"2026-08-11T14:31:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\\\/\"},\"wordCount\":2364,\"image\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight-ai.jpg\",\"keywords\":[\"pr-post\"],\"articleSection\":[\"Artwork\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\\\/\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\\\/\",\"name\":\"Vascular Dementia Market is Projected to Boost at a Moderate Growth Rate of 4.5% During the Forecast Period (2026-2036) | DelveInsight - Ciel Charlotte\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight-ai.jpg\",\"datePublished\":\"2026-08-11T14:31:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/2d677d9028fd00936e6868e285e439fb\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\\\/#primaryimage\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight-ai.jpg\",\"contentUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight-ai.jpg\",\"width\":1536,\"height\":1024,\"caption\":\"Vascular Dementia Market is Projected to Boost at a Moderate Growth Rate of 4.5% During the Forecast Period (2026-2036) | DelveInsight\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vascular Dementia Market is Projected to Boost at a Moderate Growth Rate of 4.5% During the Forecast Period (2026-2036) | DelveInsight\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#website\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/\",\"name\":\"Ciel Charlotte\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/2d677d9028fd00936e6868e285e439fb\",\"name\":\"Maya Collins\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Maya-Collins-1-96x96.jpeg\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Maya-Collins-1-96x96.jpeg\",\"contentUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Maya-Collins-1-96x96.jpeg\",\"caption\":\"Maya Collins\"},\"description\":\"Maya Collins is a technology and business writer covering emerging trends, digital innovation, startups, and the evolving role of technology in modern businesses. Her work focuses on making complex industry developments easy to understand, with a practical approach that highlights how new technologies affect companies, professionals, and consumers. Maya is particularly interested in AI, software, digital transformation, and the changing technology landscape.\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/author\\\/maya-collins\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vascular Dementia Market is Projected to Boost at a Moderate Growth Rate of 4.5% During the Forecast Period (2026-2036) | DelveInsight - Ciel Charlotte","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Vascular Dementia Market is Projected to Boost at a Moderate Growth Rate of 4.5% During the Forecast Period (2026-2036) | DelveInsight - Ciel Charlotte","og_description":"The vascular dementia market is expected to increase due to the rising prevalence of the disease driven by the aging global population, the growing incidence of stroke and other vascular risk factors, and improved diagnostic capabilities enabling earlier\u2026","og_url":"https:\/\/development.brstdev.com\/cielcharlotte\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\/","og_site_name":"Ciel Charlotte","article_published_time":"2026-08-11T14:31:00+00:00","og_image":[{"width":1536,"height":1024,"url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/08\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight-ai.jpg","type":"image\/jpeg"}],"author":"Maya Collins","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Maya Collins","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\/#article","isPartOf":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\/"},"author":{"name":"Maya Collins","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/2d677d9028fd00936e6868e285e439fb"},"headline":"Vascular Dementia Market is Projected to Boost at a Moderate Growth Rate of 4.5% During the Forecast Period (2026-2036) | DelveInsight","datePublished":"2026-08-11T14:31:00+00:00","mainEntityOfPage":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\/"},"wordCount":2364,"image":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\/#primaryimage"},"thumbnailUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/08\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight-ai.jpg","keywords":["pr-post"],"articleSection":["Artwork"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\/","url":"https:\/\/development.brstdev.com\/cielcharlotte\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\/","name":"Vascular Dementia Market is Projected to Boost at a Moderate Growth Rate of 4.5% During the Forecast Period (2026-2036) | DelveInsight - Ciel Charlotte","isPartOf":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#website"},"primaryImageOfPage":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\/#primaryimage"},"image":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\/#primaryimage"},"thumbnailUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/08\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight-ai.jpg","datePublished":"2026-08-11T14:31:00+00:00","author":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/2d677d9028fd00936e6868e285e439fb"},"breadcrumb":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/development.brstdev.com\/cielcharlotte\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\/#primaryimage","url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/08\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight-ai.jpg","contentUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/08\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight-ai.jpg","width":1536,"height":1024,"caption":"Vascular Dementia Market is Projected to Boost at a Moderate Growth Rate of 4.5% During the Forecast Period (2026-2036) | DelveInsight"},{"@type":"BreadcrumbList","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/vascular-dementia-market-is-projected-to-boost-at-a-moderate-growth-rate-of-4-5-during-the-forecast-period-2026-2036-delveinsight\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/development.brstdev.com\/cielcharlotte\/"},{"@type":"ListItem","position":2,"name":"Vascular Dementia Market is Projected to Boost at a Moderate Growth Rate of 4.5% During the Forecast Period (2026-2036) | DelveInsight"}]},{"@type":"WebSite","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#website","url":"https:\/\/development.brstdev.com\/cielcharlotte\/","name":"Ciel Charlotte","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/development.brstdev.com\/cielcharlotte\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/2d677d9028fd00936e6868e285e439fb","name":"Maya Collins","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/Maya-Collins-1-96x96.jpeg","url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/Maya-Collins-1-96x96.jpeg","contentUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/Maya-Collins-1-96x96.jpeg","caption":"Maya Collins"},"description":"Maya Collins is a technology and business writer covering emerging trends, digital innovation, startups, and the evolving role of technology in modern businesses. Her work focuses on making complex industry developments easy to understand, with a practical approach that highlights how new technologies affect companies, professionals, and consumers. Maya is particularly interested in AI, software, digital transformation, and the changing technology landscape.","url":"https:\/\/development.brstdev.com\/cielcharlotte\/author\/maya-collins\/"}]}},"_links":{"self":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts\/7155","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/comments?post=7155"}],"version-history":[{"count":1,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts\/7155\/revisions"}],"predecessor-version":[{"id":8454,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts\/7155\/revisions\/8454"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/media\/7156"}],"wp:attachment":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/media?parent=7155"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/categories?post=7155"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/tags?post=7155"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}